EGFR and non-small cell lung carcinoma: Various mechanisms have been reported, including EGFR mutations disrupting drug binding (e.g., C797S), activation of alternate pathways, aberrant downstream signaling and lineage plasticity leading to small cell transformation.4,5 However, over 30% of resistance mechanisms to osimertinib remain unexplained, which attracts the exploration of new resistance mechanisms and potential therapeutic strategies for the treatment of TKI-resistant NSCLC.6